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Abstract
Activated cancer-associated fibroblasts (CAFs) or myofibroblasts not only facilitate tumor growth and spread but also
affect tumor response to therapeutic agents. Therefore, it became clear that efficient therapeutic regimens should
also take into account the presence of these supportive cells and inhibit their paracrine effects. To this end, we tested
the effect of low concentrations of curcumin, a pharmacologically safe natural product, on patient-derived primary
breast CAF cells. We have shown that curcumin treatment upregulates p16INK4A and other tumor suppressor proteins
while inactivates the JAK2/STAT3 pathway. This reduced the level of alpha-smooth muscle actin (α-SMA) and the
migration/invasion abilities of these cells. Furthermore, curcumin suppressed the expression/secretion of stromal
cell-derived factor-1 (SDF-1), interleukin-6 (IL-6), matrix metalloproteinase-2 (MMP-2), MMP-9, and transforming
growth factor–β, which impeded their paracrine procarcinogenic potential. Intriguingly, these effects were sustained
even after curcumin withdrawal and cell splitting. Therefore, using different markers of senescence [senescence-
associated β-galactosidase (SA–β-gal) activity, Ki-67 and Lamin B1 levels, and bromodeoxyuridine incorporation],
we have shown that curcumin markedly suppresses Lamin B1 and triggers DNA damage–independent senescence
in proliferating but not quiescent breast stromal fibroblasts. Importantly, this curcumin-related senescence was
p16INK4A-dependent and occurred with no associated inflammatory secretory phenotype. These results indicate the
possible inactivation of cancer-associated myofibroblasts and present the first indication that curcumin can trigger
DNA damage–independent and safe senescence in stromal fibroblasts.
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Introduction
Breast cancer remains the leading cause of morbidity and second lead-
ing cause of death in women worldwide [1]. Breast carcinogenesis is
a complex process involving molecular and functional alterations in
both the epithelial and stromal compartments. Indeed, several lines
of evidence indicate that cancer-associated fibroblasts (CAFs), which
constitute a major portion of the reactive tumor stroma, actively par-
ticipate in tumor growth, invasion, and metastasis [2–4]. This involves
many chemokines, growth factors, and matrix metalloproteinases
(MMPs), which transmit the message in both directions, allowing
cooperative crosstalk between cancer cells and their stroma [3,5].
Thereby, it became clear that efficient cancer therapy should take
into account the presence of stromal cells, which could be responsible
for resistance to treatment and also for tumor recurrence [6]. To this
end, nontoxic bioactive dietary components represent a promising
strategy for cancer prevention/treatment. Curcumin, the yellow pig-
ment of turmeric, showed diverse biologic and medicinal activities
[7]. Epidemiological studies have shown reduced rate of colon carcino-
genesis in populations whose diet is rich in curcumin, which suggested
anticarcinogenic activities of this molecule [8]. It has been shown in
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various animal models and human studies that curcumin is extremely
safe even at very high doses. Phase I clinical trials showed that curcumin
is safe to humans up to 12 g/day when taken orally and caused histo-
logic improvement of precancerous lesions in some patients, suggesting
that it is biologically active at these doses [9,10]. Recently, a phase I
dose escalation trial of docetaxel plus curcumin was carried out on
patients with advanced and metastatic breast cancer and showed safety
and tolerability of the combination, with an increase in the intestinal
absorption of docetaxel [11].
Currently, most anticancer drugs are designed to kill cancer cells,
while inducing other cellular tumor suppressor processes, such as
senescence, in tumor cells or their stroma may be more efficient with
less side effects [12]. Senescence is a cell fate program characterized by
irreversible growth arrest associated with changes in cell morphology,
function, and behavior [13–15]. This program is triggered by various
stimuli and stresses that prevent aged or abnormal cells from anarchical
proliferation. Senescent cells have been shown to accumulate in a
variety of aging tissues as well as several premalignant and malignant
lesions. Because cellular senescence eliminates the proliferative capacity
of precarcinogenic or procarcinogenic cells, it is considered as a potent
tumor-suppressing mechanism [16,17]. Senescent human cells exhibit
numerous changes in gene expression, many of which relate to the
growth arrest [18]. Senescent cells also develop a senescence-associated
secretory phenotype (SASP), which is characterized by the secretion of
a wide range of growth factors, cytokines, extracellular matrix proteins,
and degradative enzymes, most of which can alter the local tissue
microenvironment [19–21].
In the present study, we have shown that curcumin inactivates
breast CAFs through induction of p16-dependent senescence with no
DNA damage.
Materials and Methods
Cells, Cell Culture, and Chemicals
Breast fibroblast cells were obtained and cultured as previously
described (Hawsawi et al., 2008). MDA-MB-231 cells were obtained
from ATCC (Manassas, VA) and were cultured following the instruc-
tions of the company. All supplements were obtained from Sigma
(St Louis, MO) except for antibiotics and antimycotic solutions, which
were obtained from Gibco (Grand Island, NY).
Cellular Lysate Preparation and Immunoblot Analysis
This has been performed as previously described [22]. Antibodies
directed against JAK2 (D2E12), pJAK2 (Tyr1007/1008), STAT3,
pSTAT3-Tyr705 (D3A7), P-pRB (Ser780), MMP-2, and MMP-9
were purchased from Cell Signaling Technology (Danvers, MA);
SDF1, interleukin-6 (IL-6; 10E5), alpha-smooth muscle actin (α-SMA),
transforming growth factor–β (TGF-β; 2AR2), Lamin B1 (119D5-F1),
and Lamin A (131C3) from Abcam (Cambridge, MA); p16 from BD
Biosciences (San Jose, CA); c-Myc (C-19), survivin (D-8), p21 (F-5),
p53 (DO-1), pRB (F-8), and glyceraldehyde 3-phosphate dehydrogenase
(GAPDH; FL-335) from Santa Cruz Biotechnology (Santa Cruz, CA);
and P-pRB (Thr356) from Abnova (Taipei, Taiwan).
RNA Purification and Reverse Transcription–Polymerase
Chain Reaction
Total RNA was purified using the TRI reagent (Sigma) according
to the manufacturer’s instructions. The concentration of RNA was de-
termined using NanoDrop ND-1000 Spectrophotometer (Nanodrop
Inc, Wilmington, DE). Single-stranded cDNA was obtained from re-
verse transcription (RT) of 1 μg of RNA using RT–polymerase chain
reaction (PCR) Kit (BD Biosciences) and following the manufacturer’s
protocol. cDNA was then amplified with 1U Taq polymerase, dNTPs
(50 mM), and primers (25 pmol each). The mixture was first heated
at 94°C for 5 minutes and then 30 cycles at 94°C for 1 minute, 55°C
for 1 minute, and 72°C for 1 minute, then 72°C for 10 minutes. PCR
products were seen after electrophoresis on ethidium bromide–stained
2% agarose gels. The respective primers were as follows: LMNB1,
5′-AAGCAGCTGGAGTGGTTGTT-3′ (forward) and 5′-TTGGA-
TGCTCTTGGGGTT-3′ (reverse); LMNA, 5′-AGCAAAGTGCGT-
GAGGAGTT-3′ (forward) and 5′-TCAGGTCACCCTCCTTCT-
TG-3′ (reverse); GAPDH, 5′-GAGTCCACTGGCGTCTTC-3′
(forward) and 5′-GGGGTGCTAAGCAGTTGGT-3′ (reverse).
Migration and Invasion Assays
Cell migration and invasion were evaluated using 24-well BD
BioCoat Matrigel Invasion Chambers as per the manufacturer’s guide-
line (BD Biosciences). In brief, 0.75 ml of migration buffer [serum-free
medium (SFM)] or chemoattractants (serum-containing medium) was
added to the lower chambers. Cells were washed three times in migra-
tion medium and 2 × 105 to 4 × 105 cells were added to the upper
wells separated by 8-μm pore size polyethylene terephthalate (PET)
membrane with thin layer of matrigel basement membrane matrix
(for invasion) or without (for migration) and incubated for 18 hours.
The membranes were stained with Diff-Quick stain (Fisher Scientific,
Fair Lawn, NJ) after removing the nonmigrated cells from the top of
the membrane with Q-tips. After air-drying, the membranes were cut
and mounted on slides with oil, and cells that had migrated to the
underside of the filter were counted using light microscope (Zeiss Axio
Observer) in five randomly selected fields. Each assay was performed in
triplicate. The results were expressed as mean ± SD of migrating cells
per fields counted.
Transfection
pLKO.1-CDKN2A-shRNA and pIRES-CDKN2A-ORF plasmids
were purchased from System Biosciences (Mountain View, CA) and
used to prepare the lentiviral supernatant. Medium was removed from
the target cells and replaced with lentiviral supernatant and incubated
for 24 hours. Transduced cells were selected after 48 hours with puro-
mycin or G418.
Viral Infection
Lentivirus-based vector bearing CDKN2A-ORF (pIRES) as well
as its respective control (System Biosciences) was used to prepare the
lentiviral supernatant from 293FT cells. Lentiviral supernatants were
collected 48 hours post-transfection, filtered, and used for infection.
Twenty-four hours later, media were replaced with complete media
and cells were grown for 3 days.
Enzyme-Linked Immunosorbent Assay
Conditioned media from 24-hour fibroblast cell cultures either
treated or not were harvested, and ELISA was performed according to
the manufacturer’s instructions (R&D Systems, Minneapolis, MN).
The OD was used at 450 nm on a standard ELISA plate reader.
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Bromodeoxyuridine and Ki-67 Immunostaining
The proportion of S phase cells was determined by assessing the levels
of bromodeoxyuridine (BrdU) and Ki-67 by immunostaining as previ-
ously described [23]. Cells were incubated at 37°C with 10 μMBrdU for
18 hours, fixed with 4% paraformaldehyde in phosphate-buffered saline
(PBS) for 10 minutes and then permeabilized with 0.2% Triton X-100
for 10 minutes at room temperature. Subsequently, cells were exposed
to the BrdU antibody (Bu20a; Dako, Carpinteria, CA) in 10% fetal calf
serum for 2 hours and then washed and incubated with the Alexa Fluor–
conjugated antibody (1:500; Molecular Probes, Grand Island, NY).
For Ki-67, cells were fixed in 1:1 acetone/methanol, and a standard
indirect immunoperoxidase procedure was applied using Ki-67 anti-
body (Abcam), followed by peroxidase-conjugated anti-rabbit antibody
(Dako). Sites of antibody binding were visualized by the deposition of
brown polymer of DAB chromogen (Novocastra Laboratories Ltd,
Buffalo Grove, IL).
The percentage of BrdU- or Ki-67–labeled cells (LI) was deter-
mined for at least 500 cells per data point and expressed as a mean
and standard error of triplicate determinations.
Assessment of SA–β-Galactosidase Activity
Endogenous senescence-associated β-galactosidase (SA–β-gal)
activity was assessed histochemically. Cells were fixed in 0.5% gluta-
raldehyde in PBS for 15 minutes and then permeabilized with
0.02% NP-40 with 0.1% sodium deoxycholate for 15 minutes,
followed by incubation (overnight at 37°C) in a 1 mg/ml solution of
X-Gal substrate (5-bromo-4-chloro-3-indolyl-BD-galactopyranoside)
with 5 mM potassium ferricyanide and 2 mM magnesium chloride
together with the above-mentioned detergents, at an acidic pH (6.0).
The proportion of β-gal–positive cells was assessed in a total count of
500 cells.
γ-H2AX Immunofluorescence Microscopy
Cells were fixed with 4% paraformaldehyde in PBS for 10 minutes
and permeabilized with 0.2% Triton X-100 for 10 minutes at room
temperature. Cells were blocked in 10% fetal calf serum (in PBS) and
incubated with γ-H2AX (Ser-139) antibody (Upstate Biotechnology,
New York, NY). Cells were then washed and incubated with Alexa
Fluor–conjugated antibody (1:500; Molecular Probes). Nuclear foci
were detected using Optika microscope.
Conditioned Media
Cells were cultured in medium ± serum for 24 hours, and then the
medium was collected and centrifuged. The resulting supernatant was
either used immediately or frozen at −80°C until needed.
Figure 1. Curcumin inactivates CAFs. (A–C and E) CAF-87 cells were challenged with curcumin (10 μM) for the indicated periods of time.
Whole-cell lysates were prepared and 50 μg of proteins were used for immunoblot analysis using the indicated antibodies. The numbers
below the bands represent fold of change compared to the level at time 0, upon normalization against GAPDH, used as internal control.
(D) CAF-87 cells were either DMSO-treated (−) or challenged with curcumin (10 μM) for 24 hours (+). Secreted levels of proteins were
determined by ELISA and shown in the histograms. Error bars represent means ± SD. *P value < .05.
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Quantification of Protein and RNA Expression Levels
The expression levels of the immunoblotted proteins were measured
using the densitometer (BIO-RAD GS-800 Calibrated Densitometer)
as previously described [22].
Statistical Analysis
Statistical analysis was performed by Student’s t test and P values
of .05 and less were considered as statistically significant.
Results
Curcumin Upregulates p16, p21, and p53 and Inhibits
STAT3-Related Secretory Phenotype in CAFs
We have previously shown that p16, p21, and p53 proteins are
downregulated in breast CAFs compared to their tumor counterpart
fibroblasts (TCFs), and these tumor suppressor proteins negatively
regulate the expression of several procarcinogenic cytokines, which
are highly expressed in these cells [2,24,25]. Therefore, we sought to
investigate the possible up-regulation of these three tumor suppressor
proteins and the inhibition of the procarcinogenic paracrine effects of
these cells using curcumin. To this end, CAF-87 cells were challenged
with curcumin (10 μM) for different periods of time (0, 4, 8, 18, and
24 hours), and protein extracts were prepared and used for immunoblot
analysis using specific antibodies. Figure 1A shows that the basal levels
of p16, p21, and p53 were indeed very low at time 0 and then increased
several folds upon curcumin treatment. This increase was sustained
during the whole treatment period (Figure 1A). Interestingly, the accu-
mulation of these tumor suppressor proteins was accompanied by a
sharp decrease in the level of α-SMA, a major marker of active stromal
fibroblasts, which became undetectable after 8 hours of treatment
(Figure 1B). Likewise, the levels of stromal cell-derived factor-1
(SDF-1) and TGF-β, which are also highly expressed in active fibro-
blasts, decreased following curcumin treatment (Figure 1B). Further-
more, curcumin strongly reduced the expression of IL-6, MMP-2,
and MMP-9, reaching undetectable levels after only 8 hours of treat-
ment (Figure 1C ). To further show this, we assessed the level of secreted
cytokines in the media upon curcumin treatment (10 μM for 24 hours)
using ELISA. Figure 1D shows that curcumin significantly reduced the
secreted levels of MMP-2, MMP-9, IL-6, SDF-1, and TGF-β. Similar
results were obtained for other CAF cells (data not shown). These
results indicate that curcumin can normalize active breast CAFs.
In an effort to elucidate the molecular mechanism underlying
curcumin-dependent repression of these genes, we investigated the pos-
sible role of curcumin in inhibiting the important transcription factor
STAT3 that regulates the expression of all these genes in addition to
p21 and p53 [26,27]. Figure 1E shows that curcumin markedly
reduced the active form of JAK2 and its downstream effector STAT3,
with no effect on their inactive forms. This indicates that curcumin
suppresses the phosphorylation of these two proteins in breast stromal
fibroblasts. To confirm this, we investigated the effect of curcumin on
some STAT3 targets. Figure 1E shows that c-Myc and survivin were
downregulated following curcumin treatment. Therefore, curcumin re-
presses cancer-prone cytokines through inhibiting the STAT3 pathway.
Curcumin Inhibits the Migration/Invasion Abilities of
Breast Stromal Fibroblasts
To further show the ability of curcumin in inactivating CAFs,
we investigated the migration/invasion abilities of curcumin-treated
Figure 2. Curcumin inhibits the migration/invasion of CAF cells and their procarcinogenic effects. (A) CAF-87 cells were first treated with
DMSO or different doses of curcumin for 24 hours and then were cultured on the upper compartments of BioCoat Matrigel chambers in
the presence of SFM. After 18 hours of incubation, cells were stained with Diff-Quick stain and then counted. (Upper panel) Representative
photographs showing invasive and migrated cells. Scale bars represent 50 μm. Histograms are depicting average numbers of invasive
and migrated cells. (B) SFCM were collected from CAF-87 cells either sham-treated or challenged with curcumin (10 μM) for 24 hours;
SFM and CpM were also used as control. These media were added separately into the lower compartments of the 24-well BD BioCoat
plates. MDA-MB-231 cells (1 × 104) were seeded onto the upper compartment of the migration (noncoated chambers) and invasion
(Matrigel Invasion Chamber) plates and incubated for 18 hours. Average numbers of migrated/invaded cells are depicted in the histograms.
Error bars represent means ± SD.
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cells. To this end, CAF-87 cells were cultured in SFM and were
either sham-treated (DMSO) or challenged with different doses of
curcumin (1, 5, and 10 μM) for 24 hours. Media were removed and
curcumin–CAF-87 as well as DMSO–CAF-87 cells were collected
and seeded with SFM into BioCoat Matrigel-coated invasion cham-
bers and uncoated chambers for migration. Complete medium
(CpM) was added to the lower chambers of the inserts as chemo-
attractant. After 18 hours of incubation, cells were stained with
Diff-Quick stain and then counted. Figure 2A (upper panel ) shows
the invading and migrating breast stromal fibroblasts, with higher
abilities for those treated with DMSO compared to those treated
with curcumin (10 μM). Indeed, the invasiveness and the migratory
abilities of curcumin-treated cells were reduced in a dose-dependent
manner reaching levels 5-fold and 25-fold lower compared to their
respective control cells (Figure 2A, lower panel ). This shows that
curcumin represses the migration/invasion abilities of active breast
stromal fibroblasts.
Curcumin Suppresses the Paracrine Proinvasive/Migratory
Effects of CAFs on Breast Cancer Cells
We have next studied the effect of curcumin on the ability of
stromal fibroblasts in enhancing the migration and invasion of human
breast cancer cells. Therefore, CAF-87 cells were either sham-treated
(DMSO) or challenged with curcumin (10 μM) for 24 hours; there-
after, the culture medium was replaced by SFM and cells were reincu-
bated for another 24 hours. Subsequently, serum-free conditioned
medium (SFCM) was collected and used to assess the effect on breast
cancer cells. We used BioCoat Matrigel-coated invasion chambers and
uncoated chambers for migration. CpM, SFM, and SFCM were added
to the upper wells with MDA-MB-231 cells, and SFM was also added
separately to the lower compartment of each chamber. After 18 hours
of incubation, cells were stained with Diff-Quick stain and then
counted. Figure 2B shows that the invasion ability of breast cancer cells
was six-fold lower in the presence of SFCM from curcumin-treated cells
(curcumin-SFCM) than in the presence of SFM conditioned with
Figure 3. Curcumin triggers senescence in CAF cells. CAF-87 cells were either sham-treated (DMSO) or challenged with curcumin (10 μM)
for 24 hours (A) cells were either immediately harvested (24) or were reincubated in fresh media for 48 hours and then were either
harvested (48) or split and reincubated for another 48 hours (split). Subsequently, cell lysates were prepared from all these cells and the
levels of various proteins were assessed by immunoblot analysis. (B) Cells were analyzed by phase contrast microscopy and Ki-67
immunostaining. Scale bars represent 50 μm. (C) Labeling index for Ki-67 and BrdU staining was determined for at least 500 cells per data
point and expressed as mean ± SD of triplicate determinations. (D) Immunofluorescence staining using BrdU antibody. Scale bars
represent 50 μm. (E) Curcumin-treated cells were split and reincubated for 48 hours in curcumin-free medium, and then SA–β-gal activity
was analyzed on cells before and after split. Scale bars represent 50 μm. (F) Total RNAwas prepared and used for RT-PCR using primers
for the indicated genes.
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DMSO-treated CAF-87 cells (DMSO-SFCM). Interestingly, the inva-
sion of MDA-MB-231 cells in the presence of curcumin-SFCM was
similar to that obtained in the presence of SFM (Figure 2B). This
indicates that curcumin completely suppressed the proinvasive secre-
tions from CAF-87 cells. Similar effects were obtained for the migration
of MDA-MB-231 cells under the same conditions (Figure 2B). These
results show that curcumin suppresses breast stromal fibroblast–
dependent induction of the migratory and invasiveness abilities of
breast cancer cells.
Curcumin Effects on Breast Stromal Fibroblasts Are Persistent
Next, we sought to test whether the effect of curcumin on breast
stromal fibroblasts is transient or persistent. To this end, CAF-87
cells were either sham-treated (DMSO) or challenged with curcumin
(10 μM) for 24 hours, and then cells were either immediately harvested
(24) or were reincubated in fresh medium for 48 hours and then were
either harvested (48) or split and reincubated for another 48 hours
(split). Subsequently, cell lysates were prepared from all these cells
and the levels of various proteins were assessed by immunoblot analysis.
Figure 3A shows that the levels of p16, p21, and p53 increased in re-
sponse to curcumin and remained at high levels or slightly increased,
despite the removal of curcumin from the media (48) and even after
splitting cells. Interestingly, this effect was accompanied by a persis-
tent sharp decrease in the level of SDF-1 and IL-6 (Figure 3A). This
clearly shows that the effect of curcumin on breast stromal fibroblasts
is persistent.
Curcumin Triggers Senescence in Breast Stromal Fibroblasts
Because the persistent effect included great increase in three impor-
tant senescence-related genes (p16, p21, and p53), we sought to in-
vestigate the possible curcumin-dependent induction of senescence in
these stromal fibroblasts. Therefore, we first investigated the effect of
curcumin on the master regulator of cell proliferation and the pRB
protein. Figure 3A shows that pRB and its phosphorylated form at
serine-780 and serine-356 were persistently downregulated upon treat-
ment with curcumin, which suggests strong inhibition of cell prolifer-
ation. Next, cells were either sham-treated (DMSO) or challenged
with curcumin (10 μM) for 24 hours, and then different senescence
features were investigated. Interestingly, curcumin treatment changed
the morphology of cells, which becamemuch larger and flat (Figure 3B).
Subsequently, we assessed cell proliferation by measuring the level of
Ki-67 and the incorporation of BrdU (two important markers of cell
proliferation) in control as well as curcumin-treated cells. Figure 3B
shows that the expression of Ki-67 is much lower in curcumin-treated
Figure 4. Dose- and time-dependent induction of senescence in response to curcumin. CAF-87 cells were treated with curcumin (10 μM)
for 24 hours or as indicated and then were harvested. (A, D, F) Cell lysates were prepared for immunoblot analysis using the indicated
antibodies. (B, C, E) Cells were fixed and the SA–β-gal activity was assessed. Scale bars represent 50 μm.
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cells than in their corresponding control cells. Indeed, the labeling
index of Ki-67 was more than five-fold lower in curcumin-treated cells
(Figure 3C). Similarly, curcumin treatment strongly reduced (10-fold)
the incorporation of BrdU (Figure 3, C and D). This clearly shows
curcumin-dependent inhibition of breast stromal fibroblast prolifera-
tion. To confirm curcumin-related induction of senescence, we mea-
sured the SA–β-gal activity in the same cells. Figure 3E shows that
curcumin-treated giant cells stained positive for SA–β-gal before and
after splitting cells. Similar results were obtained on other breast stromal
fibroblasts (Figure W1). To further show curcumin-related induction
of senescence, we made use of the recently discovered senescence
marker, Lamin B1 [28]. To this end, total RNA was purified from
control as well as curcumin-treated cells and was used for assessing the
level of Lamin B1 and Lamin A by RT-PCR. Figure 3F shows that
curcumin significantly reduced the level of Lamin B1 compared to
control cells, while the level of Lamin A remained constant. Together,
these results show curcumin-dependent induction of senescence in
breast stromal fibroblasts.
Dose- and Time-Dependent Induction of p16 and
Senescence in Response to Curcumin
Next, we investigated the effect of low curcumin doses on p16
up-regulation and the induction of senescence. Therefore, cells were
challenged with increasing doses of curcumin (0, 1, 5, and 10 μM) for
24 hours and then cell extracts were prepared and used for immunoblot
analysis. Figure 4A shows that curcumin upregulated p16 in a dose-
dependent manner, and this increase started with a curcumin dose as
low as 1 μM. Concomitantly, a dose-dependent decrease in the level
of Lamin B1 but not Lamin A was observed (Figure 4A). This suggested
the induction of senescence by low doses of curcumin. Indeed, 1 μM
curcumin strongly reduced the level of Lamin B1 (Figure 4A). To
confirm the induction of senescence at low curcumin doses, wemeasured
the SA–β-gal activity in the same cells in response to the same doses.
Figure 4B shows dose-dependent increase in the SA–β-gal activity, which
was also observed at 1 μM curcumin. This confirms the induction of
senescence at low curcumin doses and shows clear link between curcu-
min doses, p16 and Lamin B1 expression levels, and SA–β-gal activity.
Figure 5. Curcumin-dependent induction of senescence is p16-related. (A) CAF-87 cells were transfected with the indicated construc-
tions and then were treated or not with curcumin (10 μM for 24 hours) as indicated. Subsequently, cell lysates were prepared and were
used for immunoblot analysis. (B) Senescence was analyzed by measuring SA–β-gal activity on the indicated cells. (C) CAF-87 cells
expressing either control or CDKN2A-shRNA were either sham-treated (DMSO) or challenged with curcumin (10 μM) for 24 hours,
and then the SA–β-gal activity was assessed. Scale bars represent 50 μm. (D) Cells were incubated at 3% oxygen, and then SA–β-
gal activity was analyzed. Scale bars represent 50 μm. (E) Cells were either sham-treated (DMSO) or challenged with curcumin (10 μM)
for 24 hours or with γ-rays (30 Gy). Thereafter, the expression of γ-H2AX expression was investigated by immunofluorescence. Scale bars
represent 25 μm.
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We have also investigated time-dependent effect of curcumin
(10 μM) on p16 expression and senescence by treating cells for differ-
ent periods of time (0–4 hours). Figure 4C shows clear increase in the
SA–β-gal activity only after 4 hours of treatment. This senescence was
accompanied by marked increase in the expression of p16 and strong
decrease in the senescence marker Lamin B1, which became undetect-
able (Figure 4D). It is noteworthy that Lamin B1 disappeared during
the first 30 minutes of curcumin treatment, before the strong up-
regulation of p16 (Figure 4D). This indicates that 4 hours of curcumin
treatment is sufficient to trigger senescence in these cells and that
Lamin B1 down-regulation precedes, and may induce, curcumin-
related senescence.
To further elucidate the kinetics of curcumin-dependent induction
of senescence in breast stromal fibroblasts, we treated CAF-87 cells
with curcumin (10 μM) for 1 or 4 hours, and then cells were split into
two subpopulations, one was immediately withdrawn for analysis, while
the other one was reincubated in curcumin-free media for another
23 or 20 hours, respectively. As control, cells were either treated with
DMSO or with curcumin (10 μM) for 24 hours. Senescence was eval-
uated by measuring the SA–β-gal activity. Figure 4E shows that while
1 hour of treatment did not affect the SA–β-gal activity, this activity
was markedly increased and cells exhibited senescent features after
4 hours of treatment. The reincubation of cells in curcumin-free media
increased slightly the SA–β-gal activity in the 1 hour–treated cells but
did not affect this activity in the 4 hour–treated cells, which showed
an activity similar to those treated for 24 hours (Figure 4E). To fur-
ther elucidate this, we investigated the effect on the expression of the
tumor suppressor and senescence-related genes p16 and Lamin B1.
Figure 4F shows clear increase in p16 level in cells treated for only
1 hour. However, the increase in the p16 level was much stronger in
cells treated for 4 or 24 hours and also those who were reincubated
up to 24 hours in curcumin-free media (Figure 4F ). This indicates
that curcumin treatment for only 1 hour is enough to initiate the
senescence process, which will take more time to be active, even in the
absence of curcumin.
Curcumin-related Induction of Senescence Is p16-Dependent
and DNA Damage-Independent
Because p16 up-regulation was sustained upon treatment with
curcumin, which also induced senescence, we sought to investigate
the possible implication of p16 in curcumin-induced senescence in
active breast stromal fibroblasts. To this end, we ectopically expressed
p16 in CAF-87 cells (Figure 5A), and then we assessed SA–β-gal
activation in the absence of curcumin treatment. Interestingly, p16
expression changed the cellular morphology and increased SA–β-gal
activity compared to control cells (Figure 5B), suggesting that p16
up-regulation can indeed trigger senescence in these cells. To con-
firm this, we have shown that while the Lamin A level was only
slightly affected, the Lamin B1 level decreased sharply in cells express-
ing CDKN2A-ORF compared to those expressing control plasmid
(Figure 5A). However, p16 down-regulation using specific shRNA (Fig-
ure 5A) upregulated Lamin B1 and suppressed curcumin-dependent
induction of senescence, while senescence was observed in curcumin-
treated control cells wherein Lamin B1 was downregulated (Figure 5,
A and C). This indicates that curcumin-related induction of senescence
in breast stromal fibroblasts is p16-dependent.
Because senescence can also result from oxidative DNA damage,
curcumin-treated cells (10 μM) were reincubated for 24 hours at 3%
oxygen, and then we assessed the SA–β-gal activity. Figure 5D shows
clear change in the cellular morphology with senescent phenotype
and also increase in the SA–β-gal activity in curcumin-treated cells,
showing that curcumin-dependent induction of senescence is not due
to high oxygen-related oxidative damage.
To show lack of DNA damage in curcumin-treated cells, cells
were either sham-treated (DMSO) or challenged with curcumin
(10 μM) for 24 hours or with γ-rays (30 Gy) used as positive control.
Thereafter, the expression of γ-H2AX (a marker of induced DNA
double-strand breaks [29]) was investigated by immunofluorescence.
Figure 5E shows that while γ-rays induced γ-H2AX expression
(immunostaining), curcumin and DMSO did not. This indicates that
while γ-rays induced DNA double-strand breaks, curcumin did not,
suggesting that curcumin triggers senescence in a DNA damage–
independent manner.
Curcumin Does Not Trigger Senescence in Quiescent
Stromal Fibroblasts
In adult animals, most organs are composed of nonreplicative quies-
cent cells, which is not the case for tumor-composing cells. Thereby,
we sought to investigate the effect of curcumin on nonreplicative quies-
cent breast fibroblasts. To this end, 100% confluent cells were incu-
bated in SFM for 24 hours, and then they were either sham-treated
(DMSO) or challenged with curcumin (10 μM) for another 24 hours
in CpM. Figure 6A shows very low and similar activity of the SA–β-gal
in both DMSO- and curcumin-treated cells, reflecting the quiescence
Figure 6. Curcumin does not trigger senescence in quiescent cells. Confluent CAF-87 cells were incubated in SFM for 24 hours, and
then they were either sham-treated (DMSO) or challenged with curcumin (10 μM) for another 24 hours in CpM. (A) Cells were fixed and
the SA–β-gal activity was assessed. Scale bars represent 50 μm. (B) Immunoblot analysis using the indicated antibodies.
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state of these cells [30–32]. This suggested that curcumin did not trig-
ger senescence in these cells. To confirm this assumption, we assessed
the level of the senescence marker Lamin B1 and have shown that the
level of this protein, like Lamin A, did not decrease upon curcumin
treatment (Figure 6B). Furthermore, the levels of p16 and p53 were
very low to undetectable and did not increase following curcumin treat-
ment (Figure 6B). In the contrary, p53 level decreased upon curcumin
treatment (Figure 6B). This confirms that curcumin did not induce
senescence in quiescent breast stromal fibroblasts.
Discussion
Traditionally, cancer treatments targeted principally tumor cells. How-
ever, studies over the past few decades have demonstrated that cancers
do not only contain tumor cells but are very complex entities with
multiple components involved in tumor growth, invasion, and metas-
tasis. Thereby, an efficient treatment should take into account these
different compounds and also make the milieu unfavorable for tumor
growth and spread. Natural and nontoxic agents that can inhibit
cancer-stroma crosstalk by normalizing the tumor microenvironment
may boost the traditional tumor cell–directed therapy. Indeed, it has
been shown that targeting CAFs improves cancer chemotherapy by
increasing intratumoral drug uptake [33]. Furthermore, using a mouse
model of cervical cancer, it has been shown that blockade of platelet-
derived growth factor (PDGF) receptor signaling in CAFs inhibited
progression of premalignant cervical lesions and the growth of invasive
carcinomas [1]. In this line of research, and on the basis of the funda-
mental role of p16, p21, and p53 in the behavior of stromal fibroblasts,
we have shown that low concentrations of curcumin increase the level of
these three tumor suppressor proteins and consequently inhibits the
procarcinogenic effects of stromal fibroblasts by reducing the secretion
of IL-6, MMP-2, MMP-9, TGF-β, and SDF-1 and suppressing the
invasion/migration of breast cancer cells. This indicates that curcumin
could be used to normalize the expression of important tumor suppressor
genes and consequently inactivates breast CAFs. Indeed, curcumin-
treated active breast fibroblasts expressed less α-SMA, SDF1, and
TGF-β (three major markers of active fibroblasts) and reduced their
invasive and migratory abilities. Together, these results demonstrate
that active stromal fibroblasts can be inactivated (normalized) and
provide proof of principle that the application of natural products such
as curcumin might be used to normalize breast cancer–related stromal
fibroblasts and suppress their procarcinogenic effects. Therefore, curcu-
min could constitute an efficient fibroblast-directed therapeutic approach.
Intriguingly, curcumin effect on breast stromal fibroblasts persisted
after the removal of the drug and even after splitting of cells. The
change in the cellular morphology and the clear decrease in prolifera-
tion rate as well as the up-regulation of three major senescence-related
proteins, p16, p21, and p53, prompted us to investigate the possible
induction of senescence in these primary noncancerous cells. Using dif-
ferent markers of senescence (SA–β-gal, Ki-67, BrdU, and Lamin B1),
we have demonstrated curcumin-dependent induction of senescence
in CAF cells. This effect was dose-dependent starting from 1 μM for
24 hours. However, using 10 μM curcumin only, 4 hours of treatment
were sufficient to induce senescence and strong p16 up-regulation.
Interestingly, 30 minutes of treatment increased p16 level and wiped
up Lamin B1, in the absence of other senescence features (cellular
shape and increase in the SA–β-gal activity), showing that curcumin
modulates p16 and Lamin B1 expression in the absence of senescence.
It is noteworthy that the time-dependent increase in p16 level upon
curcumin treatment correlated very well with the increase in the
SA–β-gal activity, showing the importance of p16 accumulation for
senescence induction. However, Lamin B1 disappeared during the
first 30 minutes of treatment, suggesting an important role of this
protein in the initiation of the senescence process, which requires fur-
ther time to be active. Indeed, while 1 hour of treatment had only
slight effect on the SA–β-gal activity, exposing cells for 1 hour followed
by 23 hours in curcumin-free medium increased three-fold the activ-
ity of SA–β-gal and also the expression of p16. However, this effect
was not as strong as curcumin treatment for 4 or 24 hours (Figure 4,
E and F).
It has been previously shown that breast stromal fibroblast cells
enter senescence in response to X-rays (10 Gy) and reincubation
for 7 days [34]. Several other genotoxic anticancer agents were also
used to trigger senescence but mainly in cancer cells. However, the
doses and the treatment conditions varied between cell lines and the
agents used to induce senescence [35,36].
Importantly, curcumin-related senescence was p16-dependent,
but DNA damage–independent. This parallels the reduced secretory
phenotype observed upon curcumin treatment shown in Figure 1D.
In fact, it has been recently shown the possible p16-dependent induc-
tion of senescence without the associated inflammatory secretory pheno-
type [37]. This indicated that SASP is associated with the accumulation
of DNA damage, which is not the case upon curcumin treatment.
Therefore, the present results further confirm the possible induction
of senescence without SASP, which has generally procarcinogenic
effects [34,38]. In the contrary, curcumin reduced the secretion of sev-
eral procarcinogenic cytokines such as IL-6, SDF-1, MMP-2, MMP-9,
and TGF-β through inhibiting their major transactivator STAT3.
Indeed, curcumin markedly inactivated JAK2 and STAT3, which led
to down-regulation in the level of their downstream targets c-Myc and
survivin (Figure 1E). The curcumin-dependent inhibition of the JAK2/
STAT3 pathway may also explain the increase in the expression of
the tumor suppressor proteins p21 and p53, known to be under nega-
tive control of STAT3 [26,27]. Interestingly, we have also shown that
curcumin does not induce senescence in quiescent cells. This may ex-
plain lack of this effect in adult animals and human beings, because
most cells in adult organisms are resting and therefore curcumin cannot
cause senescence. Likewise, it has been recently shown that DNA-
damaging agents (doxorubicin and etoposide) and also p53 induction
do not cause senescence in quiescent cells [39]. This indicates that
quiescent cells are refractory to both DNA damage–dependent and
DNA damage–independent senescence. This could be due to the fact
that curcumin-dependent changes in senescence-related genes do not
take place, or are only minimal, in quiescent cells. Indeed, unlike in
proliferating cells, p21 and p53 were not upregulated in curcumin-
treated arrested cells (Figure 6B). This could be related to chromatin
structure and effects on gene expression.
In summary, the present results demonstrate curcumin-dependent
induction of senescence in breast CAFs, which inactivates these cells
and reduce their procarcinogenic potential. This constitutes an im-
portant step toward stromal fibroblast-directed therapy, which may
improve the outcome of the classic therapeutic regimens directed
principally toward tumor cells.
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Figure W1. Curcumin triggers senescence in different breast stromal
fibroblasts. Cells were either sham-treated (DMSO) or challenged
with curcumin (10 μM) for 24 hours, and then SA–β-gal activity
was assessed (NBF, normal breast fibroblast). Scale bars represent
50 μm.
